Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 5 New Entrants companies in Ribociclib
by Most Patent Filing In 5 Years in the India in 2022

The Ribociclib top 5 is Discovery PatSnap’ annual ranking of the top 5 Most Patent Filing In 5 Years Ribociclib New Entrants in the India. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2022, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Ribociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.
#
Company Name
Region
Tech Topics
Total
1
NATCO Pharma Ltd.
Oncology,Medicine,Health care,
...[+2]
Patent: 3
2
Fresenius Kabi Oncology Ltd.
Oncology drugs,Dosage form,Decitabine,
...[+2]
Patent: 2
3
Mylan Laboratories Ltd.
Medicine,Alcohol dependence,Substance abuse,
...[+2]
Patent: 2
4
Biophore India Pharmaceuticals Pvt Ltd.
Active ingredient,Radioimmunoassay,Diagnostic microbiology,
...[+2]
Patent: 1
5
Sun Pharmaceutical Industries Ltd.
Inhaler,Drug,Medicine,
...[+2]
Patent: 1
Page generation time: Jul 07 2025